Relmada Therapeutics (RLMD) Other Working Capital Changes (2016)

Relmada Therapeutics (RLMD) has 6 years of Other Working Capital Changes data on file, last reported at $7500.0 in Q4 2025.

• On a quarterly basis, Other Working Capital Changes rose 101.07% year-over-year to $7500.0 in Q4 2025; TTM through Dec 2025 was $88785.0, a 127.77% increase from a year earlier, with the FY2025 full-year figure at $88785.0, up 127.77% from the prior year.
• Other Working Capital Changes for Q3 2016 stood at -$6178.0, down from $31929.0 in the prior quarter.
• Over the last five years, Other Working Capital Changes for RLMD reached as high as $1.0 million in Q3 2024 and fell as low as -$1.7 million in Q4 2023.
• Historically, Other Working Capital Changes has averaged -$209392.3 across 3 years, with a median of -$204312.0 in 2024.
• On a YoY basis, Other Working Capital Changes climbed as much as 101.07% in 2025 and fell as far as 51.45% in 2025.
• Year by year, Other Working Capital Changes stood at -$1.7 million in 2023, then jumped by 57.77% to -$698342.0 in 2024, then jumped by 101.07% to $7500.0 in 2025.
• Per Business Quant data, the three most recent Other Working Capital Changes figures were $7500.0 in Q4 2025, $493119.0 in Q3 2025, and -$121783.0 in Q2 2025.